‹ ›
MYP_064922
Basic Information
Galcanezumab
Immunology ▸ Immune modulation ▸ Immunomodulatory activity
Therapeutic / Biomedical activity ▸ Enzyme replacement therapy
Standard
445 amino acids
C2168H3347N569O675S17
Standard
Sequence
QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
Physicochemical Analysis
48727.28 Da
7.60
1.30
0.45
0.0029
-0.38
0.63
0.02
42.90
67.12
0.0989
80790.00
81415.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Readable PDBLast file check: 2026-11-18T22:06:43.335135+00:00. File readability does not guarantee 3D display.
Match index: Listed
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0160373 REVIEWED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Monoclonal antibody
9606
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Immunomodulatory Enzyme replacement
Show moreShow less: Half-Life The mean serum half-life of galcanezumab is similar at all dose levels at about 25-30 days.[A33112] The elimination half-life of galcanezumab was ultimately approximately 27 days.[L4894]